nu6102 has been researched along with nu 6027 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bentley, J; Boyle, FT; Calvert, AH; Cheng, Y; Curtin, NJ; Endicott, JA; Golding, BT; Griffin, RJ; Hardcastle, IR; Jewsbury, P; Mesguiche, V; Newell, DR; Noble, ME; Parsons, RJ; Pratt, DJ; Sayle, KL; Wang, LZ | 1 |
Caldon, EC; Tadesse, S; Tilley, W; Wang, S | 1 |
1 review(s) available for nu6102 and nu 6027
Article | Year |
---|---|
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinase 2; Drug Design; Humans; Neoplasms; Protein Binding; Protein Conformation; Protein Kinase Inhibitors | 2019 |
1 other study(ies) available for nu6102 and nu 6027
Article | Year |
---|---|
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Structure; Protein Binding; Pyrimidines; Structure-Activity Relationship | 2003 |